English-arkiv - Page 17 of 25

Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan

GOTHENBURG, Sweden, August 13, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) today announced […]

Isofol’s CEO Ulf Jungnelius has subscribed for all warrants

GOTHENBURG, Sweden, August 4, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First North Premier Growth Market: ISOFOL), today announced that

A milestone is reached with the inclusion of 330 patients in the AGENT-study – opening up for the interim analysis

GOTHENBURG, Sweden, July 21, 2020 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq First North Premier Growth Market: ISOFOL), today announced that

AGENT study update with regards to COVID-19

GOTHENBURG, Sweden, July 10, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL), informs that the

Isofol’s rights issue oversubscribed

GOTHENBURG, Sweden, June 3, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the

Consortium of investors acquires subscription rights from Isofol´s founder Professor Bengt Gustavsson

GOTHENBURG, Sweden, May 29, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million

GOTHENBURG, Sweden, May 14, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the

English